Cargando…
Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab
BACKGROUND: Leronlimab, a monoclonal antibody blocker of C-C chemokine receptor type 5 originally developed to treat human immunodeficiency virus infection, was administered as an open-label compassionate-use therapeutic for coronavirus disease 2019 (COVID-19). METHODS: Twenty-three hospitalized sev...
Autores principales: | Yang, Bryant, Fulcher, Jennifer A, Ahn, Jenny, Berro, Marlene, Goodman-Meza, David, Dhody, Kush, Sacha, Jonah B, Naeim, Arash, Yang, Otto O |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665416/ https://www.ncbi.nlm.nih.gov/pubmed/33079180 http://dx.doi.org/10.1093/cid/ciaa1583 |
Ejemplares similares
-
Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019
por: Burwick, Richard M, et al.
Publicado: (2020) -
Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab
por: Agresti, Nicholas, et al.
Publicado: (2021) -
Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species
por: Chang, Xiao L., et al.
Publicado: (2022) -
Population Mobility and Aging Accelerate the Transmission of Coronavirus Disease 2019 in the Deep South: A County-Level Longitudinal Analysis
por: Zeng, Chengbo, et al.
Publicado: (2022) -
Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care
por: Olender, Susan A, et al.
Publicado: (2020)